THRD(Delisted)
Third Harmonic Bio·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 0
Bearish signal 1
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About THRD
Third Harmonic Bio, Inc.
A clinical-stage biopharmaceutical company that develops medicine for allergy and inflammation
1700 Montgomery Street, Suite 210, San Francisco, California 94111
--
Third Harmonic Bio, Inc., was incorporated under the laws of the State of Delaware on April 25, 2019. The company is a biopharmaceutical company focused on advancing the next wave of medications for skin, respiratory, and gastrointestinal inflammatory diseases. The company is developing a next-generation, highly selective, oral KIT small molecule inhibitor, a cell surface receptor that acts as a primary regulator of mast cell function and survival.
Company Financials
EPS
THRD has released its 2024 Q4 earnings. EPS was reported at -0.29, versus the expected -0.33, beating expectations. The chart below visualizes how THRD has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
